ArticleClinical ophthalmology (Auckland, N.Z.)2025
Outcomes of Treatment in Ocular Myasthenia Gravis Based on Minimal Manifestation: A Real-World Retrospective Cohort Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness caused by autoantibodies targeting acetylcholine receptors. Prednisolones improve symptoms by reducing autoantibody activity, but its optimal use, particularly in ocular myasthenia gravis (OMG), remains unclear due to limited trials and variable responses. Objective: To evaluate the clinical efficacy, optimal dosing, and predictors of first minimal manifestation (MM) with oral prednisolone in myasthenia gravis, based on the Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS). Methods: Patients with OMG treated with oral prednisolones between 1st January 2015 and 31st December 2022 at Rajavithi Hospital were retrospectively reviewed. Baseline data, dosing, efficacy, and outcomes were analyzed using Cox regression and survival curves to identify predictors and time to first MM. Results: Of the 101 OMG, 81 patients (80.2%) achieved MM. The mean age was 46.6 ±6.9 years in the MM group and 46.2 ± 6.0 years in the non-MM group. The mean daily dose of pyridostigmine was significant higher in the MM group (152.68 ± 32.38 mg/day) compared to the non-MM group (133 ± 34.50 mg/day) (p = 0.018). The prednisolone dosage was comparable between the two groups. Seropositivity of AChRAb, thymoma, thymectomy, concurrent autoimmune diseases were notably observed in non-MM group (p < 0.05, respectively). Cox proportional hazards analysis and survival curves revealed higher pyridostigmine dosage (HR 1.713, 95% CI: 1.029-2.849, p = 0.038). Prednisolone initiation at 6-12 months reduced MM (HR 0.527, 95% CI: 0.297-0.936, p = 0.029), with further reduction observed beyond 12 months (HR 0.165, 95% CI: 0.073-0.368, p < 0.001). The presence of AChRAb, thymoma, prednisolones dosage and ophthalmic manifestations demonstrated no significant association with the achievement of minimal manifestation. Conclusion: Early prednisolone initiation (within 6 months) and higher pyridostigmine doses were linked to remission, highlighting treatment factors over demographics in OMG outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.